Indeed, Regeneron believes that the success with Ebola could potentially have ushered in “a new era in which monoclonal antibodies could be used to fight viral diseases and global pandemics.” ...

While Regeneron doesn't make vaccines specifically, its monoclonal antibody therapy provides a "passive vaccine" effect, temporarily protecting against infections. Dupixent Could Gain 30% More U.S ...

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...

Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline ...

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...

TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ... an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on ...